Drug maker Zenotech Laboratories today said reported Rs 3.41 crore loss for the quarter ended June 30, against a net loss of Rs 2.66 crore in the same period previous fiscal.
The board today approved the results for the financial year ended March 31, and first quarter ended June 30, 2009, Zenotech Laboratories said in a filing to the Bombay Stock Exchange (BSE).
The board meeting was scheduled to be held on October 9, 2009, was postponed to November 16, 2009, the filing added.
Total income declined to Rs 1.07 crore in the latest quarter ended June 30, against Rs 2.77 crore in the same period corresponding year, it said.
The company also reported net loss of Rs 10.79 crore for the quarter ended March 31, against Rs 6.65 crore in the same period previous year.
For the year ended March 31, the company reported a net loss of Rs 21.67 crore, against a net loss of Rs 14.70 crore in the same period previous fiscal.
Shares of Zenotech Laboratories today closed at Rs 115.25 on the BSE, down 0.73 per cent from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app